AstraZeneca PLC

NASDAQ:AZNUnited States

AstraZeneca PLC is a science-led biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory and immunology. Its pipeline forms a portfolio of investigational therapies in various stages of clinical development and includes the Alexion Rare Disease portfolio comprising approximately 178 projects. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its BioPharmaceuticals products include Farxiga, Lokelma, Crestor, Breztri and others. It is also focused on discovering, developing, and manufacturing of T-cell receptor therapies. It also offers investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus.

Contact Information

Headquarters

Cambridge Biomedical CampusCAMBRIDGE, United Kingdom CB2 0AA

Phone

207-304-5000

Fax

207-604-8151

Executives

Non-Executive Independent Chairman of the Board

Michel Demare

Chief Executive Officer, Executive Director

Pascal Soriot

Chief Financial Officer, Executive Director

Aradhana Sarin

Chief Executive Officer - Alexion, Chief Strategy Officer - AstraZeneca

Marc Dunoyer

Chief Human Resource Officer, Chief Compliance Officer, General Counsel

Jeffrey Pott